Matthew et al. [76] demonstrated that the administration of Janus kinase 1 (JAK1) inhibitor itacitinib after pembrolizumab (anti-PD-1) enhanced immune function and antitumor responses in mice, achieving a 67% response rate in a phase 2 clinical trial for metastatic NSCLC. This evidence concerns the gene JAK1 and non-small cell lung carcinoma.